Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_assertion type Assertion NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_head.
- NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_assertion description "[We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_provenance.
- NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_assertion evidence source_evidence_literature NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_provenance.
- NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_assertion SIO_000772 16507781 NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_provenance.
- NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_assertion wasDerivedFrom gad-20150221 NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_provenance.
- NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_assertion wasGeneratedBy ECO_0000203 NP99226.RAVYur0fxQsUycT0Pwe4VrDhkwnZKiJ3CFVa7rVjAxp-c130_provenance.